Research programme: recombinant fusion protein therapeutics - Planet Biotechnology
Alternative Names: Receptor/Ligand-Fc fusion protein therapeuticsLatest Information Update: 28 Sep 2024
At a glance
- Originator Planet Biotechnology
- Class Anti-infectives; Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronavirus infections; Infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Coronavirus-infections in USA
- 28 Sep 2024 No recent reports of development identified for research development in Infections in USA (Parenteral)
- 28 Aug 2020 Early research in Infections in USA (Parenteral)